TITLE

Novel combinations for treating metastatic breast cancer: Improving the odds

PUB. DATE
December 2009
SOURCE
American Journal of Health-System Pharmacy;12/2/2009, Issue S6, pS15
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
A quiz concerning novel combination drug therapy for the treatment of metastatic breast cancer is provided.
ACCESSION #
47627358

 

Related Articles

  • Dihydroxyanthracenedione: A Promising New Drug in the Treatment of Metastatic Breast Cancer. Yap, Hwee-Yong; Blumenschein, George R.; Schell, Frank C.; Buzdar, Aman U.; Valdivieso, Manuel; Bodey, Gerald P. // Annals of Internal Medicine;Dec81, Vol. 95 Issue 6, p694 

    Presents information on a study which described an experience with dihydroxyanthracenedione in the treatment of refractory metastatic breast cancer. Materials and methodology of the study; Results and discussion.

  • Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer. Vassey, P.A.; Roche, H.; Bisset, D.; Terret, C.; Vernillet, L.; Riva, A.; Ramazeilles, C.; Azli, N.; Kaye, S.B.; Twelves, C.J. // British Journal of Cancer;11/01/2002, Vol. 87 Issue 10, p1072 

    Reports on the Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer. Determination of the maximum tolerated dose, dose-limiting toxicity and recommended dose of docetaxel; Pharmacokinetics of docetaxel.

  • Metformin demonstrates ability to kill cancer stem cells in mice. DiMarcantonio, Tina // Endocrine Today;Oct2009, Vol. 7 Issue 12, p33 

    This article focuses on a study which examined the efficacy of metformin combined with doxorubicin in reducing tumor size and prologing remission in mice injected with human breast cancer cells.

  • Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study. Stathopoulos, G. P.; Tsavdaridis, D.; Malamos, N. A.; Rigatos, S. K.; Kosmas, Ch.; Pergantas, N.; Stathopoulos, J. G.; Xynotroulas, J. // Cancer Chemotherapy & Pharmacology;Nov2005, Vol. 56 Issue 5, p487 

    Purpose: This is a phase II study where a novel chemotherapy combination was tested in pre-treated breast cancer patients: docetaxel and irinotecan have already been established as agents for breast and colorectal cancer, respectively. Methods: Forty-eight (median age 54 years, range...

  • The potential for oral combination chemotherapy of 5'-deoxy-5-fluorouridine, a 5-FU prodrug, and cyclophosphamide for metastatic breast cancer. Yoshimoto, M.; Tada, K.; Tokudome, N.; Kutomi, G.; Tanabe, M.; Goto, T.; Nishimura, S.; Makita, M.; Kasumi, F. // British Journal of Cancer;11/3/2003, Vol. 89 Issue 9, p1627 

    Preclinical studies have demonstrated the synergistic anti-tumour activity of combination therapy with the oral cytostatics, 5'-deoxy-5-fluorouridine (5'-DFUR) and cyclophosphamide (CPA), in human breast cancer xenograft models. This study was performed to evaluate the efficacy and safety of...

  • Neoadjuvant treatments for triple-negative breast cancer (TNBC). von Minckwitz, G.; Martin, M. // Annals of Oncology;Aug2012 Supplement 6, Vol. 23 Issue suppl_6, pvi35 

    Neoadjuvant chemotherapy provides a means both of improving subsequent surgical intervention and of testing novel therapies or combinations. Historically, triple-negative breast cancer (TNBC) has responded well in the neoadjuvant setting, with rates of pathological complete response (pCR)...

  • Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Falandry, C.; Canney, P. A.; Freyer, G.; Dirix, L. Y. // Annals of Oncology;Apr2009, Vol. 20 Issue 4, p615 

    Aromatase inhibitors (AIs) are well established in the treatment of metastatic hormone-sensitive breast cancer in postmenopausal women. Cyclooxygenase (COX)-2 inhibitors have demonstrated efficacy in reducing cancer risk in animal and human studies. In several preclinical studies, combination AI...

  • Oral Vinorelbine in Breast Cancer: A Benefit for the Patients and Society. Petrelli, Fausto; Borgonovo, Karen; Cabiddu, Mary; Ghilardi, Mara; Barni, Sandro // European Journal of Clinical & Medical Oncology;2011, Vol. 3 Issue 2, p32 

    Metastatic breast cancer (BC) remains an incurable disease and clinical benefit and prolongation of time to progression are the main end points in advanced setting. A safe and feasible schedule of administration is the principal option in pretreated and symptomatic patients, as in the elderly...

  • Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary†‡. Chuang, E.; Wiener, N.; Christos, P.; Kessler, R.; Cobham, M.; Donovan, D.; Goldberg, G. L.; Caputo, T.; Doyle, A.; Vahdat, L.; Sparano, J. A. // Annals of Oncology;Oct2010, Vol. 21 Issue 10, p2075 

    Background: Ixabepilone is a semisynthetic epothilone B analogue that is active in taxane-resistant cell lines and has shown activity in patients with refractory breast and ovarian cancer. We carried out a phase I trial of ixabepilone plus pegylated liposomal doxorubicin (PLD) in patients with...

  • Tykerb, Herceptin Work Together in Breast Cancer.  // Bioworld Week;5/26/2008, Vol. 16 Issue 21, p2 

    The article reports on the Phase III trial which reveals that the combination of cancer drug Tykerb from GlaxoSmithKline PLC and Herceptin from Genentech Inc. works better in heavily pre-treated breast cancer. The study showed that the women pre-treated with the combination of Tykerb and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics